Future studies are needed to evaluate the utility of ADMC, sensitized with tumor targeting IgE, to examine anti-tumor activity and toxicity in in vivo cancer models to further validate this potential new cancer immunotherapy strategy. This evidence concerns the gene IGHE and neoplasm.